Healthcare Education - Synergy Biologics

Healthcare Equity

Advancing Regenerative Medicine with Access for All

At Synergy Biologics we are committed to advancing healthcare equity by providing safe, effective, and accessible human cellular and tissue-based products (HCT/Ps) to all patients, regardless of their background or socioeconomic status.

We strive to bridge gaps in regenerative medicine by partnering with healthcare providers, fostering innovation, and ensuring our solutions reach underserved communities.

Through ethical sourcing, responsible manufacturing, and strategic collaborations, we aim to improve patient outcomes and expand access to life-changing therapies for all.

Our patients love working with us

Hear from our Patients

I'm not shackled by this condition any more.

Living with Hidradenitis Suppurativa (HS) is incredibly challenging due to chronic pain, odor, and emotional toll. However, amnion transplants recommended by Dr. Gordon at Baton Rouge General offered me hope, significantly reducing recovery time and post-op pain while providing lasting relief and newfound confidence. I urge fellow HS sufferers to explore all treatment options and remember that there is hope for a better quality of life. Read Full Story

Daniel L.

Physician Perspective

Advancing Healing, Trusted by Physicians

Dr. Gabriel Galan

Medical Director at Ascension St. Vincent’s Riverside Wound Care Center

Learn More. Do More. Heal More.

Educational Resources

White Paper

Examining Costs and Readmissions in Patients Treated with surgiGRAFT™ Versus Another Allograft Product and Standard of Care

IRB

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Case Study

Innovative Healing: The Role of SurgiGRAFT™ AC in Treating Incisional Dehiscence Following Abdominal Surgery

Background

68-year-old male, multiple abdominal surgeries, underwent two exploratory laparoscopic, one for small bowel resection, and one for transverse colon resection. At two-week post op, the patient developed an incisional dehiscence. Decision made by physician to pursue weekly amniotic graft placement to help progress patients healing rate due to the protein factors present in surgiGRAFT™ AC.

Procedure & Treatment

The patient was managed with standard of care debridement and wet-to-dry dressings for one month. The wound had shown symptoms of stagnant closure after 4 weeks with standard of care treatment. Physician decided to discontinue traditional SOC and begin SurgiGRAFT™ AC (Amnion/Chorion Membrane) every week. SurgiGRAFT™ AC provides a barrier that supports healing and provides the wound with the signaling factors and proteins necessary for the development of granulation tissue in acute and chronic closures.

Patient Outcomes

Peer Connection

Connect with fellow physicians to share insights, clinical experiences, and best practices in regenerative medicine and wound care.